Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06322212 · ClinicalTrials.gov registry record · Early Phase 1

Type 2 Diabetes and Blood Brain Barrier Improvement

A Early Phase 1 study of Type2diabetes, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Early Phase 1
Development phase
52
Enrollment target
1
Study location

NCT06322212 is a Early Phase 1 study of Type2diabetes that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 52 participants, below the 492-participant average among 19 other Type2diabetes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06322212, a Early Phase 1 study of Type2diabetes, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Early Phase 1
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsules) can improve function. Patients will be asked to come to UCLA two times three months apart and each visit will last about 2.5-3 hours.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Thiamine

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-08-01
Est. Completion 2027-03-31
Phase Early Phase 1

What the Registry Record Tells You About NCT06322212

The ClinicalTrials.gov registry entry for NCT06322212 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 492-participant average among 19 other Type2diabetes trials with a reported enrollment target (89% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type2diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06322212 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06322212 about?

NCT06322212 is a clinical study titled "Type 2 Diabetes and Blood Brain Barrier Improvement". The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsu...

What is the current status of trial NCT06322212?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2024-08-01. Estimated completion is 2027-03-31.

What conditions does trial NCT06322212 study?

This clinical trial studies the following conditions: Type2diabetes.

What interventions are being tested in trial NCT06322212?

The interventions under investigation include: Placebo (OTHER), Thiamine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06322212?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06322212 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type2diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.